オメル・ブルチャク・ビニジエル医師は、イズミールのメディカルポイント国際病院の消化器内科医です。消化管がんの早期発見と炎症性腸疾患に注力しています。ビニジエル医師は韓国大学医学部で国際的なトレーニングを修了しました。手技およびロボット支援技術を用いて、肝臓、膵臓、消化器系の複雑な疾患を治療します。
ボアズ・リーバーマン医師は、シェバ医療センターの整形外科腫瘍科の部長です。成人および小児の骨軟部肉腫の治療を専門としています。リーバーマン医師は、フォーブス誌のイスラエルのトップドクターリストに選出されました。機能的再建を伴う四肢温存がん手術に注力しています。リーバーマン医師は、トロントのマウントサイナイ病院およびプリンセス・マーガレットがんセンターでフェローシップを修了しました。
ソン・ファヨン医師は消化器専門医です。専門分野は消化器がん（胃がん、食道がん）および高度内視鏡検査（胃カメラ、大腸カメラ、ESD、ポリープ切除術）です。また、GERD（胃食道逆流症）、胃炎、肝炎、ピロリ菌感染症、肝疾患など、消化器および肝臓疾患の治療も行っています。
ソン医師は、仁済大学一山白病院で消化器内科のフェローシップを修了しました。仁済大学、嘉泉大学、仁荷大学の医学部で臨床教授を務めた経験があります。現在は、ナウン病院消化器センターのセンター長を務めています。
認定：韓国内科学会、韓国消化器内視鏡学会、韓国消化器病学会の正会員。WKBLドーピング委員会委員。
主要論文：原因不明の肝細胞癌、オーバーラップ症候群を伴う原発性胆汁性肝硬変、ラミブジン耐性慢性B型肝炎の治療、およびHBV関連肝硬変におけるクレブジンの使用。
パク・ソンジン医師は消化器内科医です。内視鏡検査および胃カメラ、大腸カメラ、ポリープ切除術、ESD（内視鏡的粘膜下層剥離術）などの高度な処置を専門としています。また、肝硬変、膵炎、肝炎、ヘリコバクター・ピロリ感染症を含む消化器および肝疾患の治療も行っています。
中央大学で医学博士号および内科学修士号を取得。中央大学病院にて内科レジデントおよび消化器内科フェローシップを修了。
嘉泉大学医学部および仁荷大学医学部の臨床教授を務めています。大韓内科学会、大韓消化器内視鏡学会、大韓消化器病学会、大韓膵胆道学会の正会員です。
ヒラ・マゲン博士は、シェバ医療センターのイスラエルを代表する血液腫瘍内科医です。多発性骨髄腫およびアミロイドーシスユニットを率いています。マゲン博士は、複雑な形質細胞疾患および高リスク骨髄腫の治療を専門としています。彼女は、革新的なポイント・オブ・ケアCAR-T療法プログラムの主任研究員です。彼女の研究は、高度な免疫療法を日常の臨床ケアにもたらしています。
エラド・ヤコビ博士は、イスラエルにおける小児CAR-T細胞療法のパイオニアです。シェバ医療センターの小児細胞療法センターを率いています。ヤコビ博士は、再発性および高リスクの小児白血病やリンパ腫の治療を専門としています。ジョンズ・ホプキンス大学および米国国立がん研究所でフェローシップを修了しました。
ヤーコフ・ローレンス医師は、シェバ医療センターの放射線腫瘍科部長です。精密放射線治療と神経腫瘍学を専門としています。ローレンス医師は、膵臓がんの疼痛管理のための腹腔神経叢ラジオサージェリー（放射線外科）の先駆者です。専門分野における最高の名誉の一つであるFASTROの称号を保持しています。
エイタン・アハロン・ベン＝アミ医師は、イスラエルのシェバ医療センターで腫瘍学部門を率いています。ダナ・ファーバー癌研究所で肉腫および骨腫瘍学を専門としました。ベン＝アミ医師は、がん研究を推進するためにシェバ臨床研究機構を設立しました。希少な骨腫瘍や軟部組織肉腫を個別化プロトコルで治療しています。
アイリス・クヴェンツェル博士は、シェバ医療センターの小児血液腫瘍科医であり、骨髄移植の専門家です。エドモンド＆リリー・サフラ小児病院にて、ユーイング肉腫や骨肉腫などの小児肉腫を治療しています。クヴェンツェル博士は、複雑な小児がんに対して標的療法と細胞治療を統合した治療を行っています。また、テルアビブ大学医学部の教員も務めています。
キム・テギュン医師は消化器内科医です。膵胆道疾患および癌（膵炎、膵嚢胞、膵癌、胆嚢炎、胆石症、胆道癌など）を専門としています。また、ERCPを含む高度な内視鏡検査も行います。消化管腫瘍、胃・大腸ポリープ、胃癌、粘膜下腫瘍（SMT）の治療も行っています。
学歴・経歴：全北大学校医学部医学士。蔚山大学校医学修士。全北大学校病院インターンシップ。退役軍人健康サービス医療センター内科レジデント。仁済大学校海雲台白病院および峨山医療センター消化器内科フェローシップ。
職歴：光州退役軍人病院および退役軍人健康サービス医療センターの担当医および専門医。
ホセバ・レボジョ・リセアガ医師は、キロンサルド・アリカンテの臨床腫瘍医です。個別化されたがん治療と転移性乳がんに対する遺伝子ベースの治療に注力しています。レボジョ・リセアガ医師は、多職種連携・個別化腫瘍学の教授として教鞭をとっています。前立腺がん、大腸がん、甲状腺がんなど、さまざまな疾患を治療しています。
アヴィハイ・シモニ医師は、シェバ医療センターの骨髄移植部門のディレクターです。複雑な血液がんの治療を専門としています。MDアンダーソンがんセンターで専門フェローシップを修了しました。シモニ医師は、高リスク患者に対して同種および自家移植を行っています。テルアビブ大学の教授であり、血液学のチェアマンを務めています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
アブラハム・アヴィグドール博士は、シェバ医療センター血液学研究所の所長です。リンパ腫、CAR-T療法、複雑な血液がんの分野における世界的権威です。アヴィグドール博士は、イスラエル・リンパ腫ワーキンググループを設立しました。2026年にニューズウィーク誌によって世界第7位にランクされたクリニックの運営を支援しています。
ゾハール・ドタン医師は、シェバ医療センターの泌尿器科部長です。腫瘍マーカー血液検査と遺伝子プロファイリングを併用し、精密な癌治療計画を立てています。
ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。
ヤイール・バー博士は、シェバ医療センターの癌センターの副所長であり、胸部腫瘍内科医です。進行非小細胞肺癌の治療において、個別化免疫療法および標的療法を専門としています。分子生物学の博士号（PhD）を取得しており、免疫療法耐性に焦点を当てた研究室を主導しています。
ショップマン教授は、ウィーン総合病院の胃食道腫瘍ユニットを率いています。胃がんおよび食道がんの外科的治療を専門としています。
Choi Han Yong医師は、サムスン医療センターの泌尿器科を統括しています。高度な診断評価を通じて泌尿器がんを特定することを専門としています。